Program
zimberelimab
Also written as “Zimberelimab”, “GLS-010” and “AB122”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasm Metastasis · Biliary Tract Neoplasms, led by 5 companies.
Drug pageZimberelimab: every studyMany companies study it; this page follows only the 20 they lead. All 51 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Gloria Biosciencesits history only | 74 open or running | phase 3since Aug 19, 2022 | Aug 28, 2018 | Dec 2026phase 2 · NCT05909436 |
| Arcus Biosciencesits history only | 60 open or running | phase 3since Oct 3, 2022 | Jul 17, 2018 | none ahead |
| Gilead Sciences | 43 open or running | phase 3since Aug 12, 2022 | Apr 26, 2018 | Jun 2028phase 3 · NCT05502237 |
| Otsukaits history only | 22 open or running | phase 3since Jul 3, 2026 | Jul 27, 2021 | Jun 2027phase 1 · NCT04999761 |
| RemeGenits history only | 11 open or running | phase 2since Nov 23, 2023 | Nov 23, 2023 | Jun 30, 2027phase 2 · NCT06155396 |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany and Strata Oncology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 26, 2018First study: phase 2 study in Metastatic Urothelial CancerFirst studyNCT03547973 · 502 enrolled · United States, France, Germany and more
- Jun 9, 2020Named zimberelimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, GLS-010, AB122
- Feb 5, 2021Phase 1 study in Advanced Solid TumorsNCT04747470 · 13 enrolled · United States
- Aug 12, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05502237 · 1,021 enrolled · United States, Argentina, Austria and more
- Nov 21, 2022Phase 2 study in Lung NeoplasmsNCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
Ahead
- Jun 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05502237
- Sep 2029Primary completion: phase 2 study in Lung NeoplasmsNCT05633667
- Apr 2030Primary completion: phase 2 study in Metastatic Urothelial CancerNCT03547973
TargetBeta
“A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 4 Gilead Sciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more | 2 | Active, not recruiting | Sep 2029 | 192 |
| NCT05502237Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jun 2028 | 1,021 |
| NCT04747470Advanced Solid Tumors · United States | 1 | Terminated | Nov 7, 2022 | 13 |
| NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more | 2 | Active, not recruiting | Apr 2030 | 502 |
How it is read
Names in the registry
- “Zimberelimab”, 10 entries
- “GLS-010”, 6 entries
- “AB122”, 2 entries
- “GLS-012+GLS-010”, 2 entries
- “Zimberelimab (ZIM)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Uterine Cervical Neoplasms, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Neoplasm Metastasis, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.